Skip to content
中文产业新闻精选评分77Chinese source

argenx FcRn 拮抗剂 efgartigimod ALKIVIA 3 期达主要终点，再鼎享大中华区权益

argenx FcRn靶向药3期成功，再鼎享大中华区权益

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.